News
RYTM
43.33
+3.69%
1.54
Viking Therapeutics gains on early data for oral weight loss therapy
Seeking Alpha · 2d ago
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
3 analysts have maintained Buy ratings on Rhythm Pharmaceuticals, Beam Therapeutics and Glaukos. The 3 stocks are in the Healthcare sector. Analyst consensus on Glau Kos is a Strong Buy with an average price target of $105.13. 3 analysts have recently weighed in on the 3 stocks with bullish sentiments.
TipRanks · 2d ago
Weekly Report: what happened at RYTM last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at RYTM last week (0311-0315)?
Weekly Report · 03/18 09:35
Weekly Report: what happened at RYTM last week (0304-0308)?
Weekly Report · 03/11 09:34
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
Weekly Report: what happened at RYTM last week (0226-0301)?
Weekly Report · 03/04 09:35
Weekly Report: what happened at RYTM last week (0219-0223)?
Weekly Report · 02/26 09:38
Rhythm Pharmaceuticals (RYTM) Price Target Increased by 5.49% to 56.67
NASDAQ · 02/24 17:23
Rhythm Pharmaceuticals: Expanding Markets and Innovation Fuel Buy Rating Upgrade
TipRanks · 02/23 13:26
3 Best Stocks to Buy Now, 2/23/2024, According to Top Analysts 
TipRanks · 02/23 11:19
Rhythm Pharmaceuticals: Action Too Specific
Seeking Alpha · 02/23 11:03
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Imcivree Performance and Market Expansion
TipRanks · 02/22 19:25
Analyst Expectations For Rhythm Pharmaceuticals's Future
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in development and commercialization of therapies for patients with rare diseases. Rhythm Pharmaceuticals has an average price target of $49.89. 9 analysts have shared their insights on the company in the last three months.
Benzinga · 02/22 18:00
Buy Rating Affirmed for Rhythm Pharmaceuticals Amidst Growth Potential Despite Quarterly Sales Variability
TipRanks · 02/22 17:35
Rhythm Pharmaceuticals Price Target Maintained With a $50.00/Share by Needham
Dow Jones · 02/22 17:35
Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $50 Price Target
Benzinga · 02/22 17:25
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Prescription Growth and Promising Clinical Developments
TipRanks · 02/22 12:47
Rhythm Pharmaceuticals Announces Upcoming Financial Control Deficiencies
TipRanks · 02/22 12:12
Rhythm Pharmaceuticals Q4 EPS $(0.70) Misses $(0.69) Estimate, Sales $24.23M Miss $25.38M Estimate
Rhythm Pharmaceuticals reported quarterly losses of $0.70 per share. The company reported quarterly sales of $24.23 million which missed the analyst consensus estimate of $25.38 million by 4.52%. The company also reported a 175.70 percent increase in sales from the same period last year.
Benzinga · 02/22 12:05
More
Webull provides a variety of real-time RYTM stock news. You can receive the latest news about Rhythm Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.